FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure

The FDA approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy (e.g., nuts, milk, eggs) in certain individuals 1+ years for the reduction of allergic reactions (Type I), including reducing the risk of anaphylaxis, that may occur with accidental exposure to 1 or more foods.

Patients who take Xolair must continue to avoid foods to which they are allergic.

Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

For details, read the FDA news release.